Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2003
10/16/2003US20030195222 Substituted pyrimidinones and pyrimidinthiones
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195177 Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
10/16/2003US20030195175 Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
10/16/2003US20030195172 Novel phosphonic acid compounds as inhibitors of serine proteases
10/16/2003US20030195171 Method for inhibiting bone resorption with an alendronate and vitamin D formulation
10/16/2003US20030195170 Tablets for treatment of osteoporosis
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195167 Administering lovastain for treament of autoimmune diseases (rheumatoid arthritis)
10/16/2003US20030195143 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteoanabolically active substance
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194456 Extract of the leaves and/or stem of Argemone mexicana plant for treatment of psoriasis and related biochemical and immunological disorders
10/16/2003US20030194397 Introducing platelet-rich plasma into and around the site of the injury
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481701A1 Benzoxazinone-derived compounds, their preparation and use as medicaments
10/16/2003CA2481463A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481035A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480482A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
10/16/2003CA2480084A1 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2462708A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/15/2003EP1352912A1 Parathyroid hormone analogues for the treatment of osteoporosis
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352659A1 Combination drugs
10/15/2003EP1352656A2 Combination therapy using a TNF binding protein for treating TNF-mediated diseases
10/15/2003EP1352063A2 Receptor nucleic acids and polypeptides
10/15/2003EP1352062A2 Improved growth hormone molecules
10/15/2003EP1352054A2 Aspergillus ochraceus 11 alpha hydrolase and oxidoreductase
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351973A1 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
10/15/2003EP1351958A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351953A1 Quinoline derivatives as nk-3 antagonists
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351933A1 Il-8 receptor antagonists
10/15/2003EP1351930A2 Protease inhibitors
10/15/2003EP1351929A1 Nitric oxide synthase inhibitor phosphate salt
10/15/2003EP1351924A2 Diamines as modulators of chemokine receptor activity
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351702A1 Trem-1 splice variant for use in modifying immune responses
10/15/2003EP1351697A2 Pharmaceutical for stimulating the regeneration of tissues
10/15/2003EP1351694A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/15/2003EP1351682A1 Regulation of lipids and/or bone density and compositions therefor
10/15/2003EP1351680A2 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
10/15/2003EP1351672A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
10/15/2003EP1351584A2 Nutritional composition for a bone condition
10/15/2003EP1268471B1 N-heterocyclic derivatives as nos inhibitors
10/15/2003EP1259508B1 Novel biarylcarboxamides
10/15/2003EP1183037B1 Compositions for modulating immune response and for the treatment of inflammatory disease
10/15/2003EP1007096B1 Arginine silicate inositol complex and use thereof
10/15/2003EP0784480B1 Use of erythropoietin in the treatment of rheumatoid arthritis
10/15/2003CN1449385A Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
10/15/2003CN1449377A Inhibitors of alpha4 mediated cell adhesion
10/15/2003CN1449287A Fused pyrrolocarbazoles against inflammation
10/15/2003CN1449278A Lung surfactant compositions with dynamic swelling behaviour
10/15/2003CN1448176A Medicine for treating osteoporosis and its preparing process
10/15/2003CN1448149A Chinese medicine preparation for treating hyperosteogeny
10/15/2003CN1124139C Chinese medicine powder for treating rheumatoid arthritis
10/15/2003CN1124130C Pharmaceutical preparation comprising colodronate as active ingredient and silicified microcrystalline cellulose as excipient
10/14/2003US6632945 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain
10/14/2003US6632920 Immunology; diagnosing cancer, nervous system, brain, sleep, psychological, and disorders
10/14/2003US6632836 To treat autoimmune disorders, cardiac arrhythmias and the like
10/14/2003US6632834 Compositions and methods for treating conditions responsive to estrogen
10/14/2003US6632830 ACE-2 inhibiting compounds and methods of use thereof
10/14/2003US6632807 (2R,4S)-(−)-[N-(4-diethoxyphosphorylmethyl)phenyl]-1,2,4,5- tetrahydro-4-methyl-7,8-methylenedioxy-5-oxo-3-benzothiepin-2-carboxamide
10/14/2003US6632804 Therapeutically effective amount of ferrous ion and a therapeutically effective amount of an ascorbate
10/14/2003US6632647 Use of strains of parapoxvirus ovis against organ fibrosis
10/14/2003US6632449 Compositions and kits comprising a defined boron compound and methods of their preparation
10/14/2003US6632176 Products and methods for brachytherapy
10/14/2003CA2385777A1 Use of anti-tnf.alpha.antibodies and another drug
10/14/2003CA2340221C Injectable formulations of nanoparticulate naproxen
10/09/2003WO2003083080A2 Mixed- cell gene therapy
10/09/2003WO2003082921A1 Lactoferrin
10/09/2003WO2003082872A1 Novel pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/09/2003WO2003082869A1 Azaindoles as inhibitors of c-jun n-terminal kinases
10/09/2003WO2003082868A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
10/09/2003WO2003082862A1 Anti-inflammatory morpholin-acetamide derivatives
10/09/2003WO2003082841A1 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
10/09/2003WO2003082840A1 κ-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE
10/09/2003WO2003082839A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
10/09/2003WO2003082837A1 Hydroxymorpholinone derivative and medicinal use thereof
10/09/2003WO2003082829A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003WO2003082827A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
10/09/2003WO2003082813A2 Improvements in pharmaceutical compositions
10/09/2003WO2003082808A1 Benzamide derivatives
10/09/2003WO2003082807A2 Amino acids with affinity for the alpha-2-delta-protein
10/09/2003WO2003082787A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082777A2 Novel glucocorticoid receptor ligands
1 ... 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 ... 820